Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Novartis announces REACH3 trial of Jakavi reaches primary endpoint » 12:47
12/04/20
12/04
12:47
12/04/20
12:47
NVS

Novartis

$91.29 /

+1.06 (+1.17%)

, INCY

Incyte

$82.92 /

+0.25 (+0.30%)

Detailed results from the…

Detailed results from the pivotal Phase III REACH3 study demonstrate Jakavi significantly improved outcomes across a range of efficacy measures in patients with steroid-refractory/dependent chronic graft-versus-host disease, or GvHD, compared to best available therapy, Novartis (NVS) announced. The results of REACH3, which the company calls "the first successful, randomized Phase III trial in chronic GvHD," were presented today during the 62nd American Society of Hematology Annual Meeting & Exposition, or ASH. REACH3 is jointly sponsored by Novartis and Incyte (INCY). In REACH3, patients treated with Jakavi achieved significantly greater overall response rate compared to BAT at Week 24, the primary endpoint of the study. Jakavi also demonstrated statistically significant and clinically meaningful improvements in key secondary endpoints, the company said. David Feltquate, Head Hematology Development Unit, Novartis, added: "Jakavi is the first treatment to demonstrate efficacy in a large-scale randomized clinical trial in steroid-refractory/dependent chronic GvHD, and with these meaningful data we look forward to advancing discussions with regulatory authorities."

ShowHide Related Items >><<
NVS Novartis
$91.29 /

+1.06 (+1.17%)

INCY Incyte
$82.92 /

+0.25 (+0.30%)

NVS Novartis
$91.29 /

+1.06 (+1.17%)

12/03/20 Argus
Novartis price target raised to $112 from $100 at Argus
11/25/20 UBS
Novartis price target raised to CHF 99 from CHF 98 at UBS
11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
INCY Incyte
$82.92 /

+0.25 (+0.30%)

11/06/20 RBC Capital
Incyte price target lowered to $86 from $96 at RBC Capital
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
NVS Novartis
$91.29 /

+1.06 (+1.17%)

INCY Incyte
$82.92 /

+0.25 (+0.30%)

NVS Novartis
$91.29 /

+1.06 (+1.17%)

NVS Novartis
$91.29 /

+1.06 (+1.17%)

INCY Incyte
$82.92 /

+0.25 (+0.30%)

Hot Stocks
Incyte: Jakafi improved outcomes in patients in REACH3 trial » 12:32
12/04/20
12/04
12:32
12/04/20
12:32
INCY

Incyte

$83.13 /

+0.46 (+0.56%)

, NVS

Novartis

$91.40 /

+1.17 (+1.30%)

Incyte (INCY) announced…

Incyte (INCY) announced that detailed results from the pivotal Phase 3 REACH3 study demonstrate Jakafi significantly improved outcomes across a range of efficacy measures in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease compared to best available therapy. The results of REACH3, the first successful, randomized Phase 3 trial in chronic GVHD, were highlighted in a press briefing today and will be presented during the 62nd American Society of Hematology Annual Meeting & Exposition. REACH3 is jointly sponsored by Incyte and Novartis (NVS). "The results from this large, randomized study further emphasize the role Jakafi can play as a meaningful option for patients with chronic GVHD, for whom new treatments are urgently needed," said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapies, Incyte. "These data are important for patients living with GVHD and their physicians as they represent the continued success of Jakafi in the chronic form of the disease, a historically difficult-to-treat condition." In REACH3, patients treated with Jakafi achieved significantly greater overall response rate compared to BAT at Week 24, the primary endpoint of the study6. Jakafi also demonstrated statistically significant and clinically meaningful improvements in key secondary endpoints: Patients receiving Jakafi had a significant improvement in failure-free survival versus patients receiving BAT. Patients treated with Jakafi also had greater improvements in patient-reported symptoms than those treated with BAT, as measured by the rate of responders who achieved a reduction of greater than or equal to 7 points of total symptom score from baseline of the modified Lee Symptom Score. Additionally, best overall response rate, defined as any response up to week 24, was achieved in 76.4% of patients in the Jakafi arm compared to 60.4% in the BAT arm. The median duration of response was 6.2 months in the BAT arm, but was not yet reached in the Jakafi arm. No new safety signals were observed in REACH3, and adverse events attributable to treatment were consistent with the known safety profile of Jakafi.

ShowHide Related Items >><<
NVS Novartis
$91.40 /

+1.17 (+1.30%)

INCY Incyte
$83.13 /

+0.46 (+0.56%)

INCY Incyte
$83.13 /

+0.46 (+0.56%)

11/06/20 RBC Capital
Incyte price target lowered to $86 from $96 at RBC Capital
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
NVS Novartis
$91.40 /

+1.17 (+1.30%)

12/03/20 Argus
Novartis price target raised to $112 from $100 at Argus
11/25/20 UBS
Novartis price target raised to CHF 99 from CHF 98 at UBS
11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
NVS Novartis
$91.40 /

+1.17 (+1.30%)

INCY Incyte
$83.13 /

+0.46 (+0.56%)

NVS Novartis
$91.40 /

+1.17 (+1.30%)

NVS Novartis
$91.40 /

+1.17 (+1.30%)

INCY Incyte
$83.13 /

+0.46 (+0.56%)

Conference/Events
Dicerna participates in a conference call with Truist » 10:29
12/04/20
12/04
10:29
12/04/20
10:29
DRNA

Dicerna

$23.91 /

-0.79 (-3.20%)

Conference call with…

Conference call with management will be held on December 10 at 11 am hosted by Truist.

ShowHide Related Items >><<
DRNA Dicerna
$23.91 /

-0.79 (-3.20%)

DRNA Dicerna
$23.91 /

-0.79 (-3.20%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
DRNA Dicerna
$23.91 /

-0.79 (-3.20%)

Recommendations
Cowen calls Aurinia a best idea for 2021 into FDA action date » 10:21
12/04/20
12/04
10:21
12/04/20
10:21
AUPH

Aurinia Pharmaceuticals

$15.08 /

+0.22 (+1.48%)

Aurinia Pharmaceuticals…

Aurinia Pharmaceuticals is positioned for a "meaningful inflection" into the January 22 FDA action date for voclosporin in lupus nephritis, Cowen analyst Ken Cacciatore tells investors in a research note. Citing voclosporin's efficacy and safety, combined with clinician enthusiasm and an unmet clinical need, the analyst has "strong conviction" that voclosporin should be "rapidly incorporated" into the standard of care and has $1B-plus sales potential. He calls Aurinia a best for 2021 and recommends adding to positions at current levels. Cacciatore keeps an Outperform rating on the shares with a $30 price target.

ShowHide Related Items >><<
AUPH Aurinia Pharmaceuticals
$15.08 /

+0.22 (+1.48%)

AUPH Aurinia Pharmaceuticals
$15.08 /

+0.22 (+1.48%)

11/12/20 Cantor Fitzgerald
Aurinia Pharmaceuticals price target lowered to $26 from $30 at Cantor Fitzgerald
11/03/20 H.C. Wainwright
Aurinia Pharmaceuticals price target lowered to $28 from $34 at H.C. Wainwright
08/12/20 H.C. Wainwright
H.C. Wainwright ups Aurinia target to $34, sees voclosporin LN approval by PDUFA
07/22/20 H.C. Wainwright
H.C. Wainwright 'highly confident' in approval of Aurinia's voclosporin
AUPH Aurinia Pharmaceuticals
$15.08 /

+0.22 (+1.48%)

  • 23
    Jul
  • 10
    Dec
AUPH Aurinia Pharmaceuticals
$15.08 /

+0.22 (+1.48%)

AUPH Aurinia Pharmaceuticals
$15.08 /

+0.22 (+1.48%)

Recommendations
Omeros price target raised to $25 from $20 at Maxim » 07:59
12/04/20
12/04
07:59
12/04/20
07:59
OMER

Omeros

$14.26 /

+1.82 (+14.63%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy raised the firm's price target on Omeros to $25 from $20 and keeps a Buy rating on the shares. The analyst is citing the recent CMS guidelines, which confirm that Omidria will qualify for separate payment under the ambulatory surgical center payment system as a non-opioid pain management drug. McCarthy adds that this decision marks a significant event for Omeros, as Omidria is the cash engine for the company.

ShowHide Related Items >><<
OMER Omeros
$14.26 /

+1.82 (+14.63%)

OMER Omeros
$14.26 /

+1.82 (+14.63%)

10/20/20 BofA
Omeros initiated with a Buy at BofA
10/20/20 BofA
Omeros initiated with a Buy at BofA
09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
OMER Omeros
$14.26 /

+1.82 (+14.63%)

  • 12
    Aug
  • 05
    Dec
OMER Omeros
$14.26 /

+1.82 (+14.63%)

Hot Stocks
CureVac names Antony Blanc chief business officer, chief commercial officer » 07:25
12/04/20
12/04
07:25
12/04/20
07:25
CVAC

CureVac

$101.94 /

-0.29 (-0.28%)

, GSK

GlaxoSmithKline

$37.27 /

-0.14 (-0.37%)

CureVac (CVAC) announced…

CureVac (CVAC) announced that Antony Blanc was appointed chief business officer and chief commercial officer of CureVac. In this role, he will be responsible for building the network of partnerships that will support the growth of CureVac, for developing the competitiveness and commercial relevance of the company's programs in development and for building the commercial organization. Antony Blanc previously served biotech clients in Europe as an associate partner with McKinsey & Company. Between 2009 and 2017, he developed deep and broad cross-functional expertise in vaccines by serving in several senior roles at GSK Vaccines (GSK), including leading strategic marketing, strategic pricing, joint ventures and the integration of the Novartis Vaccines business unit.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

CVAC CureVac
$101.94 /

-0.29 (-0.28%)

CVAC CureVac
$101.94 /

-0.29 (-0.28%)

11/02/20 Piper Sandler
CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
09/08/20 Jefferies
CureVac initiated with a Hold at Jefferies
09/08/20 BofA
CureVac initiated with a Buy at BofA
09/08/20 Credit Suisse
CureVac initiated with a Neutral at Credit Suisse
GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

12/03/20
Fly Intel: Top five analyst downgrades
12/03/20 UBS
GlaxoSmithKline downgraded to Neutral from Buy at UBS
11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

  • 14
    Aug
GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

CVAC CureVac
$101.94 /

-0.29 (-0.28%)

GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

CVAC CureVac
$101.94 /

-0.29 (-0.28%)

GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

CVAC CureVac
$101.94 /

-0.29 (-0.28%)

Hot Stocks
McKesson, Amgen sign strategic agreement to help improve cancer care » 07:21
12/04/20
12/04
07:21
12/04/20
07:21
MCK

McKesson

$179.13 /

-1.67 (-0.92%)

, AMGN

Amgen

$226.90 /

+0.27 (+0.12%)

McKesson (MCK) and Amgen…

McKesson (MCK) and Amgen (AMGN) have signed a strategic agreement to help improve cancer care in community oncology settings. One in five cancer patients receives an Amgen medicine, while McKesson reaches 20% of U.S. cancer patients. This multi-year agreement bridges the two companies and will focus on reducing gaps in care by optimizing access to innovative precision medicine and immuno-oncology in the community setting. This partnership will be led by Ontada, McKesson's new oncology technology and insights business. Ontada is focused on helping life sciences companies like Amgen improve patient outcomes for cancer care, from early clinical development to drug commercialization and post-launch activation of insights. Amgen and Ontada will launch various programs over the course of the partnership and build on projects that have already begun, such as those focusing on reducing gaps in molecular testing and understanding treatment patterns in the community setting. For example, Amgen and McKesson recently conducted real-world research to better understand patterns of molecular testing in advanced/metastatic non-small cell lung cancer with community oncologists with plans to publish the findings in early 2021. Through the strategic partnership, McKesson and Amgen hope to: elevate awareness on molecular testing in order to optimize care in patients that benefit from targeted therapy; uncover insights on unmet need and treatment outcomes by enriching data and insight capabilities; leverage real-world evidence to better understand and optimize the deployment of biosimilars to offer providers and their patients greater choice of therapies relative to value; co-develop new approaches to deliver immuno-oncology therapies in the community setting and optimize therapy sequencing to improve patient outcomes including supportive care.

ShowHide Related Items >><<
MCK McKesson
$179.13 /

-1.67 (-0.92%)

AMGN Amgen
$226.90 /

+0.27 (+0.12%)

MCK McKesson
$179.13 /

-1.67 (-0.92%)

11/18/20 Jefferies
Drug distributors' pullback on Amazon news an overreaction, says Jefferies
11/18/20 Goldman Sachs
McKesson upgraded to Conviction Buy from Buy at Goldman Sachs
11/17/20 Goldman Sachs
Goldman says Amazon news likely to pressure entire pharmacy supply chain
11/13/20 Mizuho
McKesson price target raised to $178 from $150 at Mizuho
AMGN Amgen
$226.90 /

+0.27 (+0.12%)

11/23/20 Mizuho
Cytokinetics regaining omecamtiv could add $3 per share, says Mizuho
11/23/20 H.C. Wainwright
Cytokinetics price target lowered to $22 from $43 at H.C. Wainwright
11/23/20 Piper Sandler
Piper keeps $25 target on Cytokinetics after Amgen returns omecamtiv mecarbil
11/16/20 Oppenheimer
Amgen price target lowered to $274 from $280 at Oppenheimer
MCK McKesson
$179.13 /

-1.67 (-0.92%)

AMGN Amgen
$226.90 /

+0.27 (+0.12%)

MCK McKesson
$179.13 /

-1.67 (-0.92%)

AMGN Amgen
$226.90 /

+0.27 (+0.12%)

MCK McKesson
$179.13 /

-1.67 (-0.92%)

AMGN Amgen
$226.90 /

+0.27 (+0.12%)

MCK McKesson
$179.13 /

-1.67 (-0.92%)

AMGN Amgen
$226.90 /

+0.27 (+0.12%)

Hot Stocks
Clover announces data for COVID-19 S-Trimer vaccine candidates » 05:14
12/04/20
12/04
05:14
12/04/20
05:14
GSK

GlaxoSmithKline

$37.27 /

-0.14 (-0.37%)

, DVAX

Dynavax

$5.18 /

-0.065 (-1.24%)

Clover Biopharmaceuticals…

Clover Biopharmaceuticals announced clinical data from its Phase 1 trial demonstrating that its protein-based COVID-19 S-Trimer vaccine candidates in combination with adjuvants from either GlaxoSmithKline (GSK) or Dynavax (DVAX) induces strong immune responses, including neutralizing antibodies and cell-mediated immunity, as well as favorable safety and tolerability profiles in 150 adult and elderly participants. The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. No serious adverse events related to the vaccine candidates studied were reported. The majority of adverse events were mild and transient. S-Trimer adjuvanted with GSK's pandemic adjuvant system induced neutralizing antibody titers in 100% of participants at the selected 9 microgram S-Trimer dose in both adult and elderly groups, with geometric mean titers, or GMT, greater than 1:1,800. CpG-1018/alum-adjuvanted S-Trimer induced neutralizing antibodies in 100% of adult participants at the selected 30 microgram S-Trimer dose with GMT greater than 1:1,000, and seroconversion was observed in 88% in elderly. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. Preliminary results from stability studies have demonstrated that S-Trimer is stable at 2-8 degrees Celsius for at least six months and stable at room temperature and 40 degrees Celsius for at least one month, in line with the adjuvants tested. Thus, the ability of Clover's COVID-19 vaccine candidates to be stored in standard refrigeration temperatures makes them suitable for broad global distribution based on current results. Based on the Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners said they are confident to enter late-stage clinical development for both adjuvanted vaccines. A global Phase 2/3 efficacy study of the S-Trimer vaccine candidate in combination with GSK's pandemic adjuvant system is expected to begin in December. Clover intends to initiate a separate pivotal clinical trial of the S-Trimer vaccine candidate in combination with Dynavax's advanced CpG 1018 adjuvant plus alum in the first half of 2021.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

DVAX Dynavax
$5.18 /

-0.065 (-1.24%)

GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

12/03/20
Fly Intel: Top five analyst downgrades
12/03/20 UBS
GlaxoSmithKline downgraded to Neutral from Buy at UBS
11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
DVAX Dynavax
$5.18 /

-0.065 (-1.24%)

11/06/20 H.C. Wainwright
Dynavax price target raised to $14 from $12 at H.C. Wainwright
08/07/20 H.C. Wainwright
Dynavax price target lowered to $12 from $14 at H.C. Wainwright
08/03/20 H.C. Wainwright
Dynavax price target raised to $14 from $12 at H.C. Wainwright
07/16/20 William Blair
Dynavax has 'attractive asset' in CpG 1018, says William Blair
GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

DVAX Dynavax
$5.18 /

-0.065 (-1.24%)

  • 22
    May
GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

DVAX Dynavax
$5.18 /

-0.065 (-1.24%)

GSK GlaxoSmithKline
$37.27 /

-0.14 (-0.37%)

DVAX Dynavax
$5.18 /

-0.065 (-1.24%)

Conference/Events
Nasdaq, in association with Morgan Stanley to hold a virtual conference » 04:55
12/04/20
12/04
04:55
12/04/20
04:55
AKAM

Akamai

$103.97 /

+0.52 (+0.50%)

, ZG

Zillow Group

$111.21 /

-0.74 (-0.66%)

, YNDX

Yandex

$69.32 /

+0.12 (+0.17%)

, TSCO

Tractor Supply

$134.81 /

-1.95 (-1.43%)

, SRCL

Stericycle

$69.67 /

-0.21 (-0.30%)

, QLYS

Qualys

$92.72 /

-0.86 (-0.92%)

, PTC

PTC

$108.09 /

+0.88 (+0.82%)

, POOL

Pool Corp.

$330.23 /

-9.2 (-2.71%)

, PODD

Insulet

$255.86 /

+0.71 (+0.28%)

, PFPT

Proofpoint

$108.86 /

+1.97 (+1.84%)

, ZI

ZoomInfo

$45.59 /

+2.6 (+6.05%)

, OLED

Universal Display

$233.18 /

+1.23 (+0.53%)

, ALNY

Alnylam

$131.06 /

+1.53 (+1.18%)

, ANSS

Ansys

$337.66 /

+2.75 (+0.82%)

, DOX

Amdocs

$65.74 /

-0.29 (-0.44%)

, EBAY

eBay

$50.28 /

-1.085 (-2.11%)

, EQIX

Equinix

$692.83 /

+2.46 (+0.36%)

, HBAN

Huntington Bancshares

$12.98 /

+0.16 (+1.25%)

, HSIC

Henry Schein

$66.42 /

-0.03 (-0.05%)

, INTU

Intuit

$363.69 /

+8.21 (+2.31%)

, LITE

Lumentum

$87.87 /

+0.71 (+0.81%)

, ON

ON Semiconductor

$29.10 /

+0.135 (+0.47%)

Nasdaq 43rd Virtual…

Nasdaq 43rd Virtual Investor Conference will be held on December 1-4.

ShowHide Related Items >><<
ZI ZoomInfo
$45.59 /

+2.6 (+6.05%)

ZG Zillow Group
$111.21 /

-0.74 (-0.66%)

YNDX Yandex
$69.32 /

+0.12 (+0.17%)

TSCO Tractor Supply
$134.81 /

-1.95 (-1.43%)

SRCL Stericycle
$69.67 /

-0.21 (-0.30%)

QLYS Qualys
$92.72 /

-0.86 (-0.92%)

PTC PTC
$108.09 /

+0.88 (+0.82%)

POOL Pool Corp.
$330.23 /

-9.2 (-2.71%)

PODD Insulet
$255.86 /

+0.71 (+0.28%)

PFPT Proofpoint
$108.86 /

+1.97 (+1.84%)

ON ON Semiconductor
$29.10 /

+0.135 (+0.47%)

LITE Lumentum
$87.87 /

+0.71 (+0.81%)

INTU Intuit
$363.69 /

+8.21 (+2.31%)

HSIC Henry Schein
$66.42 /

-0.03 (-0.05%)

HBAN Huntington Bancshares
$12.98 /

+0.16 (+1.25%)

EQIX Equinix
$692.83 /

+2.46 (+0.36%)

EBAY eBay
$50.28 /

-1.085 (-2.11%)

DOX Amdocs
$65.74 /

-0.29 (-0.44%)

ANSS Ansys
$337.66 /

+2.75 (+0.82%)

ALNY Alnylam
$131.06 /

+1.53 (+1.18%)

AKAM Akamai
$103.97 /

+0.52 (+0.50%)

AKAM Akamai
$103.97 /

+0.52 (+0.50%)

11/12/20 Piper Sandler
Akamai price target lowered to $120 from $125 at Piper Sandler
10/15/20 DA Davidson
Fastly price target lowered to $105 from $115 at DA Davidson
10/15/20 Piper Sandler
Piper says buy Akamai, Cloudflare on Fastly related selloff
10/08/20 FBN Securities
Cloudflare initiated with an Outperform at FBN Securities
ZG Zillow Group
$111.21 /

-0.74 (-0.66%)

11/19/20 Piper Sandler
Home sales data reinforces Piper Sandler's constructive view of real estate
11/09/20 Wedbush
Zillow Group price target raised to $118 from $80 at Wedbush
11/09/20 Citi
Zillow Group price target raised to $130 from $85 at Citi
11/06/20 Stifel
Zillow Group price target raised to $90 from $77 at Stifel
YNDX Yandex
$69.32 /

+0.12 (+0.17%)

11/24/20 BofA
Yandex upgraded to Buy from Neutral at BofA
10/30/20 Jefferies
Yandex downgraded to Hold from Buy at Jefferies
10/29/20 Goldman Sachs
Yandex reinstated with a Buy at Goldman Sachs
09/23/20
Fly Intel: Top five analyst downgrades
TSCO Tractor Supply
$134.81 /

-1.95 (-1.43%)

10/22/20 Baird
Tractor Supply price target raised to $170 from $162 at Baird
10/22/20 Baird
Tractor Supply results robust as company re-invests forward, says Baird
10/19/20 RBC Capital
Tractor Supply price target raised to $167 from $162 at RBC Capital
10/16/20 Baird
Tractor Supply survey shows demand remains firm, says Baird
SRCL Stericycle
$69.67 /

-0.21 (-0.30%)

10/15/20 Berenberg
Stericycle initiated with a Buy at Berenberg
08/07/20 BMO Capital
Stericycle price target raised to $68 from $56 at BMO Capital
06/03/20 Baird
Baird reiterates Stericycle as Environmental Services best idea
05/15/20 Barrington
Stericycle downgraded to Market Perform from Outperform at Barrington
QLYS Qualys
$92.72 /

-0.86 (-0.92%)

10/22/20 Goldman Sachs
Qualys downgraded to Sell from Neutral at Goldman Sachs
09/09/20 Loop Capital
Qualys initiated with a Buy at Loop Capital
09/08/20 Loop Capital
Qualys initiated with a Buy at Loop Capital
08/11/20 Wedbush
Qualys price target raised to $120 from $110 at Wedbush
PTC PTC
$108.09 /

+0.88 (+0.82%)

11/30/20 Deutsche Bank
PTC price target raised to $120 from $100 at Deutsche Bank
10/15/20 Mizuho
PTC price target raised to $105 from $100 at Mizuho
10/12/20 Deutsche Bank
PTC price target raised to $100 from $95 at Deutsche Bank
POOL Pool Corp.
$330.23 /

-9.2 (-2.71%)

11/11/20 Stephens
Pool Corp. resumed with an Equal Weight at Stephens
10/23/20 KeyBanc
Pool Corp. price target raised to $400 from $335 at KeyBanc
10/05/20 Longbow
Pool Corp. on track for 'beat and raise' Q3, says Longbow
06/19/20 Baird
Pool Corp. price target raised to $271 from $258 at Baird
PODD Insulet
$255.86 /

+0.71 (+0.28%)

11/05/20 Wells Fargo
Insulet price target raised to $266 from $250 at Wells Fargo
11/03/20 Piper Sandler
Clinical Trials update positive for Insulet, says Piper Sandler
10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
08/11/20 Piper Sandler
Medtronic acquisition of Companion 'a smart decision,' says Piper Sandler
PFPT Proofpoint
$108.86 /

+1.97 (+1.84%)

11/30/20
Fly Intel: Top five analyst upgrades
11/30/20 Truist
Proofpoint upgraded to Buy from Hold at Truist
11/16/20 SMBC Nikko
Proofpoint initiated with an Outperform at SMBC Nikko
11/02/20
Fly Intel: Top five analyst downgrades
ZI ZoomInfo
$45.59 /

+2.6 (+6.05%)

11/19/20
Fly Intel: Top five analyst upgrades
11/19/20 Morgan Stanley
ZoomInfo upgraded to Overweight from Equal Weight at Morgan Stanley
11/05/20 Lake Street
TechTarget price target raised to $51 from $43 at Lake Street
11/05/20 RBC Capital
ZoomInfo upgraded to Outperform from Sector Perform at RBC Capital
OLED Universal Display
$233.18 /

+1.23 (+0.53%)

10/30/20 Deutsche Bank
Universal Display price target raised to $220 from $205 at Deutsche Bank
09/25/20 Citi
KLA on top, Amkor at bottom of Citi's Semiconductor rankings
08/07/20 Needham
Universal Display upgraded to Buy from Hold at Needham
07/27/20 Oppenheimer
Opco upgrades Universal Display to Outperform on favorable 2021 setup
ALNY Alnylam
$131.06 /

+1.53 (+1.18%)

11/24/20 BMO Capital
Alnylam price target raised to $183 at BMO Capital on early Oxlumo approval
11/24/20 Piper Sandler
Piper reiterates Overweight rating on Alnylam after Oxlumo approved
09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
ANSS Ansys
$337.66 /

+2.75 (+0.82%)

11/24/20 Credit Suisse
Ansys initiated with an Outperform at Credit Suisse
10/27/20 RBC Capital
Ansys price target raised to $348 from $310 at RBC Capital
10/26/20 Stifel
SAP news impact may be company-specific for software sector, says Stifel
08/04/20 Guggenheim
Ansys price target raised to $350 from $278 at Guggenheim
DOX Amdocs
$65.74 /

-0.29 (-0.44%)

11/11/20 JPMorgan
Amdocs upgraded to Overweight with $75 target at JPMorgan
11/11/20 JPMorgan
Amdocs upgraded to Overweight from Neutral at JPMorgan
02/05/20 Oppenheimer
Amdocs price target raised to $85 from $77 at Oppenheimer
EBAY eBay
$50.28 /

-1.085 (-2.11%)

11/27/20 Truist
Amazon to claim 42c of every e-commerce dollar spent, says Truist
11/04/20 BMO Capital
PayPal price target lowered to $193 from $200 at BMO Capital
11/03/20 KeyBanc
PayPal price target lowered to $215 from $230 at KeyBanc
11/03/20 Morgan Stanley
PayPal growth potential looks even better after Q3, says Morgan Stanley
EQIX Equinix
$692.83 /

+2.46 (+0.36%)

12/03/20 Mizuho
Mizuho initiates data center REIT sector with positive outlook
12/02/20 Mizuho
Equinix initiated with a Buy at Mizuho
11/03/20 RBC Capital
Equinix price target lowered to $825 from $845 at RBC Capital
10/29/20 Wells Fargo
Equinix price target lowered to $825 from $840 at Wells Fargo
HBAN Huntington Bancshares
$12.98 /

+0.16 (+1.25%)

10/26/20
Fly Intel: Top five analyst upgrades
10/26/20 Wedbush
Huntington Bancshares upgraded to Outperform at Wedbush
10/26/20 Wedbush
Huntington Bancshares upgraded to Outperform from Neutral at Wedbush
07/31/20 Wolfe Research
Huntington Bancshares initiated with an Outperform at Wolfe Research
HSIC Henry Schein
$66.42 /

-0.03 (-0.05%)

10/28/20 Cleveland Research
Henry Schein estimates for second half raised at Cleveland Research
05/06/20 Barrington
Henry Schein downgraded to Market Perform from Outperform at Barrington
04/07/20 Goldman Sachs
Henry Schein upgraded to Buy from Neutral at Goldman Sachs
04/02/20 Wolfe Research
Henry Schein upgraded to Outperform from Peer Perform at Wolfe Research
INTU Intuit
$363.69 /

+8.21 (+2.31%)

11/20/20 Morgan Stanley
Intuit price target raised to $455 from $400 at Morgan Stanley
11/20/20 Oppenheimer
Intuit price target raised to $382 from $355 at Oppenheimer
11/20/20 Wells Fargo
Intuit price target raised to $400 from $380 at Wells Fargo
11/20/20 RBC Capital
Intuit price target raised to $415 from $405 at RBC Capital
LITE Lumentum
$87.87 /

+0.71 (+0.81%)

11/06/20
Fly Intel: Top five analyst initiations
11/06/20 MKM Partners
Lumentum assumed with a Buy at MKM Partners
11/03/20 JPMorgan
Lumentum price target raised to $100 from $97 at JPMorgan
10/19/20 Northland
Fabrinet upgraded to Outperform following pullback at Northland
ON ON Semiconductor
$29.10 /

+0.135 (+0.47%)

11/16/20 Needham
ON Semiconductor price target raised to $33 from $30 at Needham
11/16/20 B. Riley Securities
ON Semiconductor price target raised to $34 from $33 at B. Riley Securities
11/13/20 Piper Sandler
ON Semiconductor price target raised to $32 from $28 at Piper Sandler
11/04/20 KeyBanc
KeyBanc lays out possible M&A candidates as semi consolidation heats ups
ZI ZoomInfo
$45.59 /

+2.6 (+6.05%)

ZG Zillow Group
$111.21 /

-0.74 (-0.66%)

YNDX Yandex
$69.32 /

+0.12 (+0.17%)

TSCO Tractor Supply
$134.81 /

-1.95 (-1.43%)

SRCL Stericycle
$69.67 /

-0.21 (-0.30%)

QLYS Qualys
$92.72 /

-0.86 (-0.92%)

PTC PTC
$108.09 /

+0.88 (+0.82%)

POOL Pool Corp.
$330.23 /

-9.2 (-2.71%)

PODD Insulet
$255.86 /

+0.71 (+0.28%)

PFPT Proofpoint
$108.86 /

+1.97 (+1.84%)

ON ON Semiconductor
$29.10 /

+0.135 (+0.47%)

OLED Universal Display
$233.18 /

+1.23 (+0.53%)

LITE Lumentum
$87.87 /

+0.71 (+0.81%)

INTU Intuit
$363.69 /

+8.21 (+2.31%)

HSIC Henry Schein
$66.42 /

-0.03 (-0.05%)

HBAN Huntington Bancshares
$12.98 /

+0.16 (+1.25%)

EQIX Equinix
$692.83 /

+2.46 (+0.36%)

EBAY eBay
$50.28 /

-1.085 (-2.11%)

DOX Amdocs
$65.74 /

-0.29 (-0.44%)

ANSS Ansys
$337.66 /

+2.75 (+0.82%)

ALNY Alnylam
$131.06 /

+1.53 (+1.18%)

AKAM Akamai
$103.97 /

+0.52 (+0.50%)

  • 02
    Dec
  • 20
    Aug
  • 25
    Jun
  • 04
    Jun
  • 13
    May
  • 12
    May
ZG Zillow Group
$111.21 /

-0.74 (-0.66%)

YNDX Yandex
$69.32 /

+0.12 (+0.17%)

QLYS Qualys
$92.72 /

-0.86 (-0.92%)

ON ON Semiconductor
$29.10 /

+0.135 (+0.47%)

LITE Lumentum
$87.87 /

+0.71 (+0.81%)

INTU Intuit
$363.69 /

+8.21 (+2.31%)

HBAN Huntington Bancshares
$12.98 /

+0.16 (+1.25%)

EBAY eBay
$50.28 /

-1.085 (-2.11%)

DOX Amdocs
$65.74 /

-0.29 (-0.44%)

ALNY Alnylam
$131.06 /

+1.53 (+1.18%)

ZI ZoomInfo
$45.59 /

+2.6 (+6.05%)

ZG Zillow Group
$111.21 /

-0.74 (-0.66%)

YNDX Yandex
$69.32 /

+0.12 (+0.17%)

TSCO Tractor Supply
$134.81 /

-1.95 (-1.43%)

QLYS Qualys
$92.72 /

-0.86 (-0.92%)

PTC PTC
$108.09 /

+0.88 (+0.82%)

PODD Insulet
$255.86 /

+0.71 (+0.28%)

OLED Universal Display
$233.18 /

+1.23 (+0.53%)

LITE Lumentum
$87.87 /

+0.71 (+0.81%)

INTU Intuit
$363.69 /

+8.21 (+2.31%)

HBAN Huntington Bancshares
$12.98 /

+0.16 (+1.25%)

EBAY eBay
$50.28 /

-1.085 (-2.11%)

DOX Amdocs
$65.74 /

-0.29 (-0.44%)

ALNY Alnylam
$131.06 /

+1.53 (+1.18%)

AKAM Akamai
$103.97 /

+0.52 (+0.50%)

ON ON Semiconductor
$29.10 /

+0.135 (+0.47%)

OLED Universal Display
$233.18 /

+1.23 (+0.53%)

LITE Lumentum
$87.87 /

+0.71 (+0.81%)

INTU Intuit
$363.69 /

+8.21 (+2.31%)

HBAN Huntington Bancshares
$12.98 /

+0.16 (+1.25%)

EBAY eBay
$50.28 /

-1.085 (-2.11%)

AKAM Akamai
$103.97 /

+0.52 (+0.50%)

Thursday
Hot Stocks
Alnylam selects PANTHERx Rare Pharmacy as Oxlumo partner » 13:55
12/03/20
12/03
13:55
12/03/20
13:55
ALNY

Alnylam

$131.36 /

+1.83 (+1.41%)

PANTHERx Rare Pharmacy…

PANTHERx Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals as a "very limited distribution pharmacy partner" for new drug Oxlumo, or lumasiran. The drug has been approved by the U.S. Food and Drug Administration for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients.

ShowHide Related Items >><<
ALNY Alnylam
$131.36 /

+1.83 (+1.41%)

ALNY Alnylam
$131.36 /

+1.83 (+1.41%)

11/24/20 BMO Capital
Alnylam price target raised to $183 at BMO Capital on early Oxlumo approval
11/24/20 Piper Sandler
Piper reiterates Overweight rating on Alnylam after Oxlumo approved
09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
ALNY Alnylam
$131.36 /

+1.83 (+1.41%)

ALNY Alnylam
$131.36 /

+1.83 (+1.41%)

ALNY Alnylam
$131.36 /

+1.83 (+1.41%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.